Featured news from NHIVNA
HIV-related news from NAM
AbbVie next-generation hepatitis C drugs look promising in early studies
Liz Highleyman, 2015-01-30 10:00:00
AbbVie's investigational HCV protease inhibitor
ABT-493 and NS5A inhibitor ABT-530 demonstrated good antiviral activity in
patients with genotype 1 chronic hepatitis C in a three-day monotherapy study,
as well as potent and synergistic activity against multiple HCV genotypes in
laboratory replicon studies, according to presentations at the American Association for the Study of Liver
Diseases (AASLD) Liver Meeting held recently in Boston.
The advent of direct-acting antivirals (DAAs)
that can be used in interferon-free regimens has brought about a revolution in
hepatitis C treatment. The recently approved Harvoni (Gilead Sciences' sofosbuvir/ledipasvir) and Viekirax + Exviera (AbbVie's paritaprevir/ombitasvir/ritonavir plus dasabuvir)
combinations are highly effective against HCV genotype 1, but there remains a
need for therapies that are equally active against other genotypes.